Introduction In recent years, two major breakthroughs in cancer treatment—Antibody-Drug Conjugates (ADC) and Bispecific Antibodies (referred to as “bispecifics”)—have demonstrated remarkable efficacy. So, if these two “star drugs” are used in combination, will they produce a stronger anti-cancer effect? Will the toxicity be compounded and difficult to control? A recent clinical study published in the … Read more
In 2024, the global antibody drug market is expected to experience explosive growth. According to IQVIA, global spending on biopharmaceuticals is projected to exceed $892 billion by 2028, with antibody drugs holding a significant share. In the fields of oncology and autoimmune diseases, three major technological routes—bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and proteolysis-targeting chimeras … Read more
Click to follow Xiaobai Learning Medicine BispecificADC is an active frontier, and today we will discuss whether bispecificADC is more effective than traditional monoclonal ADC in tumor toxin enrichment. Bispecific antibodies can be divided into two main categories: one type binds to two different antigens on different cells, acting as a connector, such as several … Read more